LONDON (ShareCast) - (ShareCast News) - Jersey-based investment company Flying Brands's newly-acquired subsidiary has entered into a distribution agreement with an artificial intelligence platform that will see the medical imaging software company's products available for purchase on its exchange.
Imaging Biometrics, Flying Brands' subsidiary, put IB Neuro, its premier magnetic resonance imaging dynamic susceptibility contrast perfusion solution, and its Delta T1 mapping algorithm, up for sale on the EnvoyAI exchange on Wednesday as part of a partnership that would enable immediate and widespread access to to its biomarkers for neuro-radiologists, neuro-oncologists, and neuro-surgeons.

Dr Steven Rothenberg, EnvoyAI's chief medical officer, said, "We recently added Imaging Biometrics' FDA cleared post-processing solutions to the EnvoyAI Exchange. The proprietary quantitative and automated algorithms contained in IB Neuro and IB Delta Suite provide clinicians with incredible value by producing unique imaging biomarkers that enable them to accurately monitor treatment response in brain tumor patients."

"The need to accurately quantify changes in brain tumor patients is becoming more important and yet increasingly difficult due to the challenging side effects of newer therapies and cancer fighting agents. The exclusive technology contained in IB's products overcome these difficulties and, through the unique additional information made available, aid the treatment team's ability to rapidly and objectively assess whether patients are responding to treatment," added IB's chief executive.

As of 1000 BST, shares had jumped 10.50% to 4.42p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE